semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Granulomatous Disease Chronic   The recipient fulfills by study design the The patient however, would be considered ineligible for the study only If his donor is unable to participate. DONOR Pregnant or lactating Donor unfit to receive G-CSF and undergo apheresis. (Uncontrolled hypertension, history of congestive heart failure or unstable angina, thrombocytopenia) HIV positive
Patient description: The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.

Clinical trial eligibility criteria: eligible ages (years): 3.0-21.0,  Brain Tumors Central Nervous System Tumors Histologically confirmed, newly diagnosed high-grade glioma of 1 of the following histologies Anaplastic astrocytoma Glioblastoma multiforme Gliosarcoma Primary spinal cord malignant gliomas allowed No primary brainstem tumors Has undergone surgical resection or biopsy of the tumor within the past 31 days Pre-operative and post-operative brain MRI with and without gadolinium-contrast OR pre-operative and post-operative spine MRI for spinal cord primaries Post-operative MRI not required for patients who undergo biopsy only No evidence of neuraxis dissemination
Patient description: The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Acromegaly Newly diagnosed or previously untreated acromegalic patients Lack of suppression of growth hormone (GH) nadir to <1.0 µg/L, after oral administration of 75g of glucose (oral glucose tolerance test [OGTT]) Insulin-like growth factor-I (IGF-I) levels above the upper limits of normal, i.e. 97th percentile (adjusted for age and gender)  Requires surgery for recent significant deterioration in visual fields or other neurological signs, which are related to the pituitary tumor mass No evidence of pituitary adenoma on magnetic resonance imaging (MRI) Symptomatic cholelithiasis
Patient description: The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.

Clinical trial eligibility criteria: eligible ages (years): 20.0-75.0,  Acromegaly Patients with acromegaly who have received at least one dose of B2036-PEG in the preceding study (A6291009)  Switching to other therapeutic methods for acromegaly
Patient description: The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.

Clinical trial eligibility criteria: eligible ages (years): 45.0-75.0,  Colorectal Cancer Polyps Adenomas One or more histologically verified neoplastic polyp (adenoma) that is at least 2 mm in size removed from the large bowel with the entire large bowel examined by colonoscopy and documented to be free of further polyps or areas suspicious for neoplasia within 120 days of study entry Anticipated colonoscopic follow-up three years or five years after the qualifying colonoscopy Age between 45 and 75 years at enrollment (Women)Agreement to avoid pregnancy (i.e., use of standard contraception) Willingness to forego calcium supplementation (including multivitamins containing calcium) or, for women only, option of taking calcium supplementation of 1200 mg/daily (contained in the study pills) Willingness to forego vitamin D supplementation (including multivitamins containing vitamin D) Agreement to daily dietary intake of the equivalent of not more than 1200 mg calcium Agreement to daily dietary intake of the equivalent of not more than 400 IU vitamin D Blood calcium level within normal range Blood creatinine level not to exceed 20% above upper limit of normal  General exclusionary Participation in another colorectal (bowel) study (intervention study) in the past 5 years Current participation in any other clinical trial (intervention study) Pregnancy or lactation A diagnosis of narcotic or alcohol dependence in the past 5 years A diagnosis of dementia (e.g. Alzheimer's) in the past 5 years A diagnosis of a significant psychiatric disability (e.g. Schizophrenia, refractory bipolar disorder, current severe depression) in the past 5 years Exclusions due to derangement of calcium metabolism or indications /contraindications to study agents Any diagnosis of kidney stones A diagnosis of granulomatous diseases, e.g. sarcoidosis, active chronic fungal or mycobacterial infections (tuberculosis, histoplasmosis, coccidioidomycosis, blastomycosis), berylliosis, Wegener's granulomatosis in the past 5 years A diagnosis of hyperparathyroidism or other serious disturbance of calcium metabolism in the past 5 years
Patient description: The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Acromegaly Patients who have completed all four treatment regimens in the core study CSOM230B2201 and achieved biochemical control in GH and IGF-1 levels after at least one month of pasireotide administration at any of the three doses Patients who did not experience any unacceptable adverse events or tolerability issues during the core study CSOM230B2201  Patients who experienced or developed compression of the optic chiasm causing any visual field defect during the core study CSOM230B2201 Patients who required a surgical intervention for relief of any sign or symptom associated with tumor compression during the core study CSOM230B2201 Patients who experienced or developed congestive heart failure, unstable angina, sustained ventricular tachycardia, ventricular fibrillation or acute myocardial infraction during the core study CSOM230B2201 Other protocol-defined inclusion/
Patient description: The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Acromegaly Males and females 18 and < 80 years old Recently diagnosed not previously treated patients with acromegaly Presence of a pituitary tumor (microadenoma or macroadenoma), documented by a MNR performed in the 12 weeks before enrolment Absence of nadir suppression of the nadir of GH to < 1.0 ng/mL, after oral administration of 75 g of glucose (OTTG) IGF-I levels over normal upper limits, e.g. 97 percentile (age and sex-matched) Tolerance shown with a test of a subcutaneous injection of octreotide Written Informed Consent before any procedure specific to the study. Inclus  Previously treated patients with any therapy for acromegaly, including surgery, radiotherapy, bromocriptin, and somatostatin analogues Compression of optic chiasm that produces any impairment of field of vision Need of surgery to improve any neurological sign or symptom associated with a direct incidence on the tumour Intolerance to octreotide or to any component of Sandostatin® LAR® preparation Patients with an hepatic condition such as cirrhosis, active or persisting chronic hepatitis, or other hepatopathy of fast evolution Pregnant women History of alcohol or drug abuse in the six months prior to the visit Patients suffering from any condition that may jeopardize the interpretation of study results or may impede to obtain informed consent Intake of an investigational drug during the study and 30 days before patient in this study Other protocol-defined /
Patient description: The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.

Clinical trial eligibility criteria: eligible ages (years): 18.0-85.0,  Acromegaly Growth Hormone Deficiency Pituitary Disease Age 18-75 History of acromegaly with biochemical cure documented with a normal oral glucose tolerance test (OGTT) and/or a non-elevated IGF-I without concurrent use of somatostatin analogs, dopamine agonists or GH receptor antagonists. Subjects will have been treated with medication, surgery, radiation, or a combination of these At the time of enrollment a minimum of 6 months must have elapsed since surgery No malignancy on colonoscopy performed since the diagnosis of acromegaly GHD due to surgical or radiation treatment GHD will be defined as a peak plasma GH of less than 5 ng/ml in response to an insulin tolerance test or a GH-releasing hormone (GHRH) plus arginine stimulation test GHD will also be diagnosed if IGF-I levels are below 2 standard deviations for the age-sex normal range in a patient with at least two other documented anterior pituitary hormone deficiencies  Untreated thyroid or adrenal insufficiency. Subjects on replacement therapy must be stable for at least 3 months prior to entry into the study History of malignancy except for non-melanoma skin cancer Hemoglobin <11.0 gm/dl Uncontrolled hypertension Hepatic or renal disease (aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3x upper limit of normal (ULN) or creatinine level >2.5 mg/dl) Congestive heart failure (New York Heart Association's classification system Class II-IV congestive heart failure (CHF) will be excluded) Unstable cardiovascular disease (coronary artery or cerebrovascular disease) or symptoms within one year prior to entry into the study Initiation or discontinuation of gonadal steroid therapy within 3 months of entry Diabetes mellitus, impaired fasting glucose, impaired glucose tolerance Pregnancy or nursing
Patient description: The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Acromegaly Newly diagnosed or previously untreated acromegalic patients Lack of suppression of GH nadir to <1.0 µg/L, after oral administration of 75 g of glucose (OGTT) IGF-I levels above the upper limits of normal, i.e. 97th percentile (adjusted for age and gender)  Requires surgery for recent significant deterioration in visual fields or other neurological signs, which are related to the pituitary tumor mass No evidence of pituitary adenoma on Magnetic Resonance Imaging (MRI) Symptomatic cholelithiasis Other protocol-defined
Patient description: The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Acromegaly documentation of a diagnosis of active acromegaly based on either of the following definitions: 1. the patient has never received somatostatin analog nor dopaminergic agonist or had previously received this medication but had stopped more than 3 months before visit 1 and had a mean growth hormone (GH)level >5ng/mL at visit 1; or 2. the patient was receiving treatment with a somatostatin analog (other than lanreotide autogel) or a dopaminergic agonist at visit 1, had a mean GH >3ng/mL at visit 2 (or visit 2a) and had at least a 100% increase in mean GH levels between visit 1 and visit 2 (or visit 2a)  receipt of radiotherapy for acromegaly within 3 years pituitary surgery within 3 months prior to visit 1 prior receipt of lanreotide autogel or GH antagonist anticipated need for pituitary surgery (adenomectomy) or radiotherapy during the study period known hypersensitivity to any of the test materials or related compounds clinically significant renal or hepatic abnormalities
Patient description: The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Osteoporosis Histologically/cytologically proven, non-metastatic (M0) adenocarcinoma of the prostate Life expectancy of > 12 months Initiation of treatment with the luteinizing hormone-releasing hormone agonist (LHRH-a) Lupron no more than 15 days prior or 30 days following, baseline visit Requiring treatment with LHRH agonists for prostate cancer, for a duration of at least 12 months from baseline Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2 Prior to any study-specific procedures, subject (and/or their legally authorized representative) has voluntarily signed and dated an informed consent form  Bone Metastases Current or previous use with in past 12 months of bisphosphonate. Known hypersensitivity to LHRH. Hypocalcaemia. Severe renal impairment, Abnormal liver function, Hypothyroidism, Hyperthyroidism, Bilateral hip replacement. Use of LHRH or anti-androgen medication within last 12 months. Abnormalities of esophagus which delay esophageal emptying. Inability to stand or sit upright for at least 30 minutes
Patient description: The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.

Clinical trial eligibility criteria: eligible ages (years): 16.0-999.0,  Thyroid Cancer Differentiated Thyroid Carcinoma Patients older than 16 years with well-differentiated papillary or follicular thyroid cancer stage I or II, according to the classification at time of surgery 2. Patients younger than 45 years with any size of primary papillary or follicular tumor 3. Patients older than 45 years with: 1. primary papillary tumor less than 4 cm or 2. primary follicular tumor less than 1 cm  Patients with postsurgical thyroid remnant more than 5 g 2. Patients with distant metastases 3. Patients above 45 years of age having: 1. known cervical lymph nodes metastases 2. microscopic multifocal follicular cancer 3. microscopic extraglandular invasion of follicular cancer 4. gross extraglandular invasion of papillary or follicular cancer 4. Patients with confirmed histological subtypes of well-differentiated thyroid cancer such as Hurtle cell carcinoma, insular and tall cell variants of papillary cancer. 5. Pregnant or lactating women 6. Patients with renal impairment defined as repeat serum creatinine concentrations above 1.5 mg/dl on thyroid hormone 7. Patients on chronic lithium therapy for psychiatric illness 8. Patients with current unstable cardiovascular conditions 9. Patients with severe chronic medical conditions (liver failure, severe debilitation, dehydration, sodium depletion, any other cancer requiring therapy, etc)
Patient description: The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Acute Stroke patients older than 18 years symptoms of brain infarction since less than 150 minutes NIHSS between 4 and 22 No brain hemorrhage on contrast CT-scan Signed consent form by the patient or his relatives  NIHSS above 22 or coma current oral anticoagulant or INR > 1.7 heparin treatment within the preceding 24 hours or prolonged APTT (>40seconds) platelets count < 100 000/mm3 another stroke or brain trauma within 3 months prior admission systolic blood pressure > 185 or diastolic blood pressure > 110 at the time od tPA treatment onset neurologic deficit is improving history of intracranial hemorrhage glycemia less than 0.5g/l or upper than 4g/l after treatment by Actrapid epileptic seizure at the time of stroke onset
Patient description: The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Breast Cancer Metastatic Cancer Diagnosis of stage IIB HER2/neu-expressing breast cancer 6½ years ago Received a T-cell-depleted allogeneic stem cell transplantation (SCT) from a 6/6 HLA-matched sibling donor for refractory metastatic breast cancer Developed pulmonary metastases during adjuvant chemotherapy following modified radical mastectomy Pulmonary metastases progressed after prior allogeneic SCT Responded in an objective and measurable manner to prior allogeneic lymphocyte infusion, post-transplantation chemotherapy, and trastuzumab (Herceptin®) Disease limited to the thoracic cavity Operable tumor with at least 1 cm of surgically accessible lesion Preoperative risk assessment indicating ≤ 5% risk of mortality and < 15% risk of significant morbidity for pulmonary metastasectomy Enrolled on protocol CC# 00-C-0119 Hormone receptor status not specified
Patient description: The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Knee Osteoarthritis Primary osteoarthritis of knee (confirmed by American College of Rheumatology [ACR] criteria) Requirement of regular non-steroidal anti-inflammatory drug (NSAID) therapy  Evidence of active peptic ulceration within 12 months prior to the screening visit or history of active gastrointestinal bleeding within the previous 5 years Known hypersensitivity to analgesics, antipyretics, or (including celecoxib). Other protocol-defined inclusion/